The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy

AIM: This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between pacemaker parameters and pacemaker mode along with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Mohammad, Santosa Putra, Iwan Cahyo, Bunawan, Rizki, Goenawan, Hanna, Akbar, Mohammad Rizki, Kartasasmita, Arief Sjamsulaksan, Kim, Young Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051037/
https://www.ncbi.nlm.nih.gov/pubmed/37006226
http://dx.doi.org/10.2144/fsoa-2023-0001
Descripción
Sumario:AIM: This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between pacemaker parameters and pacemaker mode along with delta sST2 levels. MATERIALS & METHODS: This prospective cohort study enrolled all symptomatic bradycardia patients aged >18 years with preserved ejection fraction who underwent permanent pacemaker (PPM) implantation. RESULTS: A total of 49 patients were included in this study. The sST2 level (ng/ml) were significantly different between prior and 1 month following PPM implantation (23.4 ± 28.4 vs 39.9 ± 63.7; p = 0.001). CONCLUSION: The early cardiac remodeling has occurred within 1 month after PPM implantation as indicated by increasing delta sST2 level.